接受白细胞介素-1抑制剂治疗的家族性地中海热患者对秋水仙碱预防治疗的依从性
该研究基于以色列Maccabi健康服务数据库,比较秋水仙碱抵抗型家族性地中海热(crFMF)接受白细胞介素-1(IL-1)抑制剂治疗者与秋水仙碱敏感型(csFMF)仅用秋水仙碱者的秋水仙碱依从性。共纳入4526例患者,108例crFMF按1:4匹配432例csFMF,两组平均用药持有率(MPR)相似(78.9±41.4 vs 82.5±80.6,P=0.5),但两组均超过50%患者MPR<80%。结论认为依从性在两组间相似,但均较差,需加强医患教育。
要点
- crFMF与csFMF两组平均MPR相似(78.9±41.4 vs 82.5±80.6,P=0.5)。
- 两组均超过50%患者秋水仙碱依从性不足(MPR<80%)。
- 作者认为需对医护人员和患者进行教育以提高依从性。
核心结论
- 与初始担忧相反,crFMF与csFMF患者的秋水仙碱依从性相似,但两组依从性均较差。
- 作者认为教育医护人员和患者对提高依从性至关重要。
研究设计与样本
- 主要结局指标为用药持有率(MPR),从首次购买秋水仙碱之日(索引日期)计算至末次购买秋水仙碱之日。
- crFMF患者按1:4比例与csFMF患者匹配。
主要发现
- 最终队列共4526例患者,其中108例(2.4%)为crFMF,与432例csFMF匹配。
- 匹配组总平均MPR相似:crFMF组78.9±41.4 vs csFMF组82.5±80.6,P=0.5。
- 按年龄或秋水仙碱使用时长分层,两组间MPR均未发现统计学显著差异。
- 两组均超过50%的患者秋水仙碱依从性不足(MPR<80%)。
关键数值与推荐
- crFMF组平均MPR为78.9±41.4,csFMF组为82.5±80.6,P=0.5。
- 依从性不足定义为MPR<80%,两组均超过50%患者符合该标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interleukin-1 (IL-1) inhibitors are approved for treating familial Mediterranean fever (FMF) that is resistant to colchicine. However, continued concomitant treatment with colchicine is imperative, as it is the only drug proven to prevent secondary amyloidosis. We aimed to compare the adherence to colchicine between patients with colchicine-resistant FMF (crFMF) who were treated with IL-1 inhibitors and patients with colchicine-sensitive FMF (csFMF) who were treated only with colchicine. METHODS: The databases of Maccabi Health Services, a 2.6-million-member state-mandated health provider in Israel were searched for patients with FMF diagnosis. The medication possession ratio (MPR), calculated from the day of the first colchicine purchase (index date) until the last colchicine purchase was the main outcome measure. Patients with crFMF were matched in a 1:4 ratio to patients with csFMF. RESULTS: The final cohort included 4526 patients. Of them, 108 (2.4%) were with crFMF, and were matched to 432 with csFMF. The total mean MPR in each of the matched groups was similar (78.9 ± 41.4 and 82.5 ± 80.6, respectively, P = 0.5). Statistically significant differences in MPR were not found between the groups according to age or duration of colchicine use. However, adherence to colchicine was insufficient (MPR<80%) among more than 50% of the patients in both groups. CONCLUSION: In contrast to initial concerns, adherence to colchicine was similar between patients with crFMF and csFMF. However, in both groups, adherence to colchicine was poor. Education of both caregivers and patients is essential to increase adherence.
引用
- Levinsky Y, Azani L, Shkalim Zemer V, et al. Adherence to colchicine prophylaxis among patients with familial Mediterranean fever treated with interleukin-1 inhibitors. Semin Arthritis Rheum. 2023. PMID: 37201215. doi:10.1016/j.semarthrit.2023.152211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。